OR WAIT null SECS
September 02, 2018
Existing software tools cannot take into account the complexity of disease.
August 02, 2018
Low-temperature chemistry enables performance of more challenging and selective chemistry.
July 23, 2018
The acquisition will place Cambrex into the finished dosage form CDMO market.
June 02, 2018
From separation systems to reactor technology, new tools are increasing the feasibility of continuous API production.
May 16, 2018
Cambrex Corporation has announced facility, equipment, and instrument upgrades at its High Point, NC facility and updated progress on expansions in Cedar City, IA.
April 24, 2018
Porton will use biocatalyst technologies from Codexis to accelerate API development for clients.
April 20, 2018
The contract renewal allows AMRI to continue to provide medicinal chemistry and ADME services for advancing drug discovery programs in neurotherapeutics.
April 02, 2018
CMOs/CDMOs that are easy to work with, have demonstrated performance track records, and plan for the future are preferred.
March 02, 2018
Assessing potential formulation and manufacturing issues in early development phases can improve a drug’s chances for success.
Highly complex APIs developed to treat rare and orphan diseases present big technical questions for contract developers.